PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 6286: Functional assessment of RECQL4 missense variants identified in RECQL4 genetic disorder-associated osteosarcomas.

View Full Paper
BRBrian RodemoyerSBSamuel Gomes BritoTNThales C. Nepomuceno

Key Points

  • To evaluate the functional impact of RECQL4 missense variants associated with genetic disorders on protein expression and localization.
  • Selected 15 RECQL4 missense variants from ClinVar and genomAD databases.
  • Generated variants using site-directed mutagenesis and transiently transfected them into U2OS osteosarcoma cells.
  • Analyzed changes in protein expression using Western blotting and assessed subcellular localization using fluorescence microscopy.
  • Benign variants showed normal expression levels compared to wildtype.
  • Pathogenic variants exhibited significantly reduced protein expression.
  • Certain missense variants of unknown significance (VUS) also displayed lower expression and impaired nuclear localization under oxidative stress.

Abstract

Abstract Pathogenic germline mutations in hRECQL4, a member of the highly conserved family of RecQ DNA helicases, are associated with three rare genetic disorders: Rothmund-Thomson Syndrome type II (RTS type II), Baller-Gerold Syndrome (BGS), and RAPADILLINO. All three disorders predispose patients to an array of cancers including osteosarcoma, breast, ovarian, and lymphoma. While most known pathogenic mutations found in RECQL4-associated disorders lead to premature protein termination, a subset of patients also display missense variants, making their clinical classification more challenging. Moreover, some missense variants of unknown significance (VUS), are present in the general population, however, their contribution to disease prevalence has remained mostly unexplored. To assess the functional impact of RECQL4 missense VUS, we selected 15 missense variants identified in RECQL4-associated disorders from the ClinVar and genomAD databases. Our dataset includes three known benign, three known pathogenic, nine VUS, and the helicase-dead K508M variant. Here, we utilize immunochemical and fluorescence microscopy techniques to assess the functional impact of these 16 RECQL4 missense variants. Using a pcDNA5-FRT-eGFP-RECQL4 construct, we generated missense variants by site-directed mutagenesis followed by transient transfection into endogenous RECQL4-silenced U2OS osteosarcoma cells in triplicate. Missense variants were analyzed by Western blotting for alterations in protein expression compared to the wildtype. While the benign variants p.(E71G) and p.(E267D) displayed expression like the wildtype as expected, pathogenic variants p.(P466L) and p.(S1079I) showed markedly reduced expression levels. Interestingly, VUS p.(L566P), p.(V768A), and p.(R1058G) also displayed reduced protein expression as compared to the wildtype, indicating a possible mechanism of pathogenicity. Furthermore, we performed fluorescence microscopy to assess the effect of the variants on subcellular localization under basal conditions and in the presence of the oxidative DNA damaging agent Streptonigrin. The pathogenic p.(P466L) variant, which is located in the nuclear localization signal (NLS), failed to localize to the nucleus, however, VUS p.(L566P), which is located downstream of the NLS, also impaired nuclear localization. Even under oxidative DNA damage conditions, which targets RECQL4 to the nucleolus, neither pathogenic p.(P466L) nor VUS p.(L566P) were capable of nuclear localization. In summary, we have successfully generated 16 RECQL4 missense variant constructs and evaluated them for both protein expression and subcellular localization under normal and oxidative DNA damaging conditions, identifying a VUS that behaves similarly to a known pathogenic variant. Citation Format: Brian Rodemoyer, Samuel Brito, Thales C. Nepomuceno, Alvaro N. Monteiro, . Functional assessment of RECQL4 missense variants identified in RECQL4genetic disorder-associated osteosarcomas abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6286.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rodemoyer et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd9ca79560c99a0a3c74https://doi.org/10.1158/1538-7445.am2026-6286
Ask AI
Helpful
Bookmark
Share
View Full Paper